Why Lantheus Holdings Stock Popped by Almost 12% Last Month

By Eric Volkman – Mar 9, 2026 at 4:43PM ESTKey PointsAlthough its adjusted net income dipped, it handily beat analyst expectations on both the top and bottom lines.It also announced a very sensible pivot in its business.February is a frigid month in much of this country, but it wasn't all that frosty for Lantheus Holdings (LNTH +10.29%). The medical device specialist unveiled its final set of financial results for 2025, ending that year on quite the high note. A pair of crushing beats In its fourth quarter, Lantheus' revenue totaled just under $407 million, up 4% from the same period in 2024. Net income not under generally accepted accounting practices (GAAP) fell at essentially the same rate to land at just under $111 million, or $1.67 per share. Image source: Getty Images. Although investors aren't typically fond of a bottom-line drop, Lantheus easily beat the $1.17-per-share consensus analyst estimate for that metric. It also crushed the average pundit revenue projection, which was slightly more than $366 million. While those two beats were impressive and encouraging, other elements in Lantheus' earnings report helped draw investors into the stock. The company announced, in its words, that it "is sharpening its strategic focus to innovative radiodiagnostics and is prioritizing its investment in the development and commercialization of innovative PET radiodiagnostics, alongside a decision to pursue value‑maximizing alternatives for radiotherapeutic assets to support long‑term growth." This makes sense because Lantheus' No. 1 product, cancer imaging agent Pylarify, is suffering sales declines. In the fourth quarter alone, its take fell by almost 10% year over year to slightly over $240 million. So, while it's still quite the revenue stream for the specialty healthcare company, there's an acute need to focus on more promising growth drivers -- like precision diagnostics. That product category leaped 22% higher in said quarter to bring in over $143 million. In the earnings release, Lantheus also provided guidance for the entirety of 2026. Management anticipates earning $1.4 billion to $1.45 billion in revenue, filtering down into non-GAAP (adjusted) per-share net profit of $5 to $5.25. The current consensus analyst estimates for the two metrics are $1.45 billion and $5.19, respectively. ExpandNASDAQ: LNTHLantheusToday's Change(10.29%) $7.47Current Price$80.03Key Data PointsMarket Cap$4.7BDay's Range$72.54 - $80.6652wk Range$47.25 - $111.29Volume115KAvg Vol960KGross Margin61.10% More where that came from 2026 looks to be quite an eventful year for Lantheus. It has no less than four products in late-stage development, all of which could win Food and Drug Administration (FDA) approval. Lantheus' new focus is entirely sensible (and, to a degree, necessary), meanwhile it's clearly doing a good job convincing its customer base to keep buying its products. I also like the company's approach to pursuing growth both organically and through selective, complementary acquisitions. I think we'll get plenty of good news from Lantheus this year, and I'm bullish on its future.Read NextFeb 27, 2025 •By David KretzmannLantheus' Pylarify Hit $1B in 2024 SalesFeb 25, 2025 •By Motley Fool YouTubeLantheus (LNTH): A 10x Opportunity in RadiopharmaceuticalsJan 29, 2025 •By Eric VolkmanWhy Lantheus Holdings Stock Got Thrashed on TuesdayNov 20, 2024 •By Eric VolkmanWhy Lantheus Holdings Stock Won Big on WednesdayJul 10, 2024 •By Keith SpeightsWhy Lantheus Holdings Stock Is Skyrocketing TodayJun 3, 2023 •By James Halley2 Medical Imaging Stocks That Are Better Buys Than Nano-XAbout the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedLantheusNASDAQ: LNTH$80.03(+10.29%)+$7.47*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.